| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/07/2006 | US6995174 for inhibiting proteases |
| 02/07/2006 | US6995167 Arylkylamine spirofuropyridines useful in therapy |
| 02/07/2006 | US6995164 Methods of treating tumors |
| 02/07/2006 | US6995162 Substituted alkylamine derivatives and methods of use |
| 02/07/2006 | US6995161 Central nervous system disorders |
| 02/07/2006 | US6995159 4-piperazin-1-yl-2-(pyridin-2-ylmethoxy)-pyrimidine, 2-(6-methyl-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine, and 2-(6-chloro-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine; for treatment of seizure and eating disorders; reduced side effects |
| 02/07/2006 | US6995156 Platelet adenosine diphosphate receptor antagonists |
| 02/07/2006 | US6995153 tachykinin receptor antagonist, in particular, an NK1 receptor antagonist; prophylactic or therapeutic agent against tachykinin receptor-related pathological conditions, including increased urinary frequency, incontinence, vomiting, inflammation |
| 02/07/2006 | US6995151 Isophthalic acid derivatives as matrix metalloproteinase inhibitors |
| 02/07/2006 | US6995150 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol |
| 02/07/2006 | US6995144 for example, 6-[2-[4-(2-fluorophenoxymethyl)piperidino]ethyl]-1H-pyrazin-2-one; therapeutic or prophylactic agent for diabetic neuralgia, HIV neuralgia, postherpetic neuralgia, nerve system disorders |
| 02/07/2006 | US6995140 Peptides and polypeptides useful for regenerating the nervous system |
| 02/07/2006 | US6995139 Cyclic undecapeptide pro-drugs and uses thereof |
| 02/07/2006 | US6995135 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments |
| 02/07/2006 | US6995011 Expression vector for use as tool in gene therapy |
| 02/07/2006 | US6994978 Human osteoclast derived cathepsin |
| 02/07/2006 | US6994959 which compete with DNA-binding sites of regulatory proteins which regulate t-cell activity (CD28 and cytokines), preventing transcription; analyzing immunocompetence; for treatment of autoimmune diseases |
| 02/07/2006 | US6994957 Using nucleic acid |
| 02/07/2006 | US6994864 Cosmetics for dermatological treatment and prevention of skin aging due to actinic radiation |
| 02/07/2006 | US6994858 Infecting the mixed cellular compositions with reovirus which selectively lyse the ras-mediated neoplastic cells in the mixed composition |
| 02/07/2006 | US6994857 A Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants) fused to albumin, is sufficient to prolong the shelf-lilfe of therapeutic protein |
| 02/07/2006 | US6994843 Delivery of stimulants through an inhalation route |
| 02/07/2006 | CA2360308C Glucocorticoid receptor modulators |
| 02/07/2006 | CA2340202C Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors |
| 02/07/2006 | CA2316082C Substituted 2-benzylamino-2-phenyl-acetamide compounds |
| 02/07/2006 | CA2311344C 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability |
| 02/07/2006 | CA2273479C 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors |
| 02/07/2006 | CA2268484C Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives |
| 02/07/2006 | CA2119783C Substituted phenserines and phenylcarbamates of (-)-eseroline, (-)-n1-noreseroline, and (-)-n1-benzylnoreseroline; as specific inhibitors of acetylcholinesterase |
| 02/02/2006 | WO2006012359A2 Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| 02/02/2006 | WO2006011670A1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE |
| 02/02/2006 | WO2006011561A1 Oligosaccharide derivative having heterocyclic ring |
| 02/02/2006 | WO2006011466A1 5-substituted-2-phenylamino-benzamide as mek inhibitor |
| 02/02/2006 | US20060025597 4-(Aminomethyl)-2-(2,6-dioxo(3-piperidyl))isoindoline-1,3-dione hydrochloride; cytokines level reduced; tumor necrosis factor inhibitors; nontoxic; anticarcinogenic agents; antitumor agents (solid/blood-borne); cardiovascular disorders; osteoporosis; antiinflammatory agents; autoimmune diseases |
| 02/02/2006 | US20060025594 Small molecule entry inhibitors |
| 02/02/2006 | US20060025581 Novel human GABA receptor proteins and polynucleotides encoding the same |
| 02/02/2006 | US20060025469 Methods for decreasing beta amyloid protein |
| 02/02/2006 | US20060025464 Benzimidazole derivatives as therapeutic agents |
| 02/02/2006 | US20060025461 Triazole derivative |
| 02/02/2006 | US20060025442 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/02/2006 | US20060025432 N-[2-[(3-Chloro-2-fluorobenzyl)thio]-6-[(2-hydroxy-1-methylethyl)amino]-4-pyrimidinyl]- 4-morpholinesulfonamide; asthma, antiallergens; rhinitis, chronic obstructive pulmonary disease, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis |
| 02/02/2006 | US20060025428 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/02/2006 | US20060025413 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 02/02/2006 | US20060025410 2,4-Pyrimidinediamine compounds and their uses |
| 02/02/2006 | US20060025407 Succinoylaminobenzodiazepines as inhibitors of Abeta protein production |
| 02/02/2006 | US20060025403 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/02/2006 | US20060025396 Isophthalic acid derivatives as matrix metalloproteinase inhibitors |
| 02/02/2006 | US20060025357 Use of agent for suppressing infection and proliferation of human immunodeficiency syndrome virus |
| 02/02/2006 | US20060025352 Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| 02/02/2006 | US20060025350 4-hydroxy-2-hydroxymethyl-pyrrolidin-3-yl 4-O-(6-deoxy- alpha -D-glucopyranosyl)- alpha -D-glucopyranoside; alpha-amylase inhibitor; antidiabetic agents, hypoglycemic agents; side effect reduction |
| 02/02/2006 | US20060025342 Administering parathyroid hormone-related protein intermittently at a dosage of at least 500 mu g/day for at least one month,to increase bone mass densityat a rate of at least 1% per month; treating osteoporosis |
| 02/02/2006 | US20060025339 Corticotropin releasing factor 2 receptor agonists |
| 02/02/2006 | US20060024798 Gene knockout; gene overexpression; liposomes |
| 02/02/2006 | US20060024792 G-protein coupled receptors |
| 02/02/2006 | US20060024772 Parathyroid hormone antibodies and related methods |
| 02/02/2006 | US20060024728 GM-CSF and/or defensin protein expression regulators in epithelial cells comprising ETS transcription factor or gene encoding the same |
| 02/02/2006 | US20060024396 Method of treating diabetes and obesity using carbohydrate absorption inhibitors |
| 02/02/2006 | US20060024373 Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
| 02/02/2006 | US20060024334 Immunotherapeutic methods and systems |
| 02/02/2006 | US20060024299 Human osteoclast derived cathepsin |
| 02/02/2006 | US20060024234 Protein markers for pharmaceuticals and related toxicity |
| 02/02/2006 | US20060024233 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 02/02/2006 | CA2573018A1 Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| 02/01/2006 | EP1621616A1 Human antihuman interleukin-18 antibody, fragment thereof and method of using the same |
| 02/01/2006 | EP1621554A1 Immunoglobulins devoid of light chains |
| 02/01/2006 | EP1621553A1 Antibodies that inhibit transport activity of peptide transporters |
| 02/01/2006 | EP1621548A2 Polypeptides, CDNAs encoding the same and utilization thereof |
| 02/01/2006 | EP1621545A2 Oligoribonucleotides and ribonucleases for cleaving RNA |
| 02/01/2006 | EP1621544A1 Remedies for diseases caused by strengthened vascular smooth muscle using 14-membered ring macrolide compounds |
| 02/01/2006 | EP1621533A1 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents |
| 02/01/2006 | EP1621212A1 Formulations comprising antisense nucleotides to connexins |
| 02/01/2006 | EP1621207A2 Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors |
| 02/01/2006 | EP1621206A1 Chimeric cytokines and uses thereof |
| 02/01/2006 | EP1621197A2 Composition comprising a steroid and an anticholinergic agent |
| 02/01/2006 | EP1621195A2 The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 02/01/2006 | EP1620445A2 Method and compositions for identifying anti-hiv therapeutic compounds |
| 02/01/2006 | EP1500654B1 Benzoxazinone derivatives, the preparation and use thereof as medicaments |
| 02/01/2006 | EP1476419B1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives |
| 02/01/2006 | EP1436293B1 Polycyclic compounds having anti-tumor activity |
| 02/01/2006 | EP1430144A4 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 02/01/2006 | EP1425281B1 Tricyclic CRF receptor antagonists |
| 02/01/2006 | EP1370548B1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same |
| 02/01/2006 | EP1328266B1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 02/01/2006 | EP1254121B1 Preparation of sulfonamides |
| 02/01/2006 | EP1235812B1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 02/01/2006 | EP1146894B1 Uses of thank protein, a tnf homologue, to inhibit growth of tumour cells |
| 02/01/2006 | EP1129204B1 Novel system for regulating transgene expression |
| 02/01/2006 | EP1119563B1 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 02/01/2006 | EP1104289B1 New oral formulation for 5-ht4 agonists or antagonists |
| 02/01/2006 | EP0994709A4 Calcium blockers to treat proliferative vitreoretinopathy |
| 02/01/2006 | EP0906119B1 Stimulation of host defense mechanisms against cancer |
| 02/01/2006 | CN1729291A Exon 1beta of PDGF receptor alpha gene and utilization thereof |
| 02/01/2006 | CN1729192A Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
| 02/01/2006 | CN1729173A N-(indolethyl-) cacloamine compounds |
| 02/01/2006 | CN1729017A A preparation and method for weight reduction |
| 02/01/2006 | CN1729010A The use of melagatran for the manufacture of a medicament for the treatment of type I diabetes mellitus |
| 02/01/2006 | CN1729002A Exemestane as chemopreventing agent |
| 02/01/2006 | CN1728993A Pharmaceutical composition comprising lumiracoxib |
| 02/01/2006 | CN1727339A Tricyclic compounds, their production and use |
| 02/01/2006 | CN1726969A Small golden pellets and preparation method |